CD177 and breast cancer: Serglycin is constitutively secreted by breast cancer cells acting in an autocrine manner via binding to cell surface receptors such as CD44, a key mesenchymal and breast cancer stem cell marker gene, and integrins, possibly through its chondroitin sulfate (CS) chains (69) (Figure 5).